FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva
Published . Updated .
FDA has approved Atebrioz (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva (FOP).
Directly affected
- No company is named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
FDA has approved Atebrioz (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva (FOP).
Source: FDA
How far Acadia Healthcare (ACHC) has moved since 27 Sep 2026
Since the first closing price after “FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva,” Acadia Healthcare (ACHC) is +8.13%. The S&P 500 fund (SPY) is +0.15% over the same days, a +7.98% difference versus the market.
Who reported a Acadia Healthcare (ACHC) trade near this story
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 2 days after publication, inside 30 days. The filing is listed beside the story “FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 16 days before publication, inside 30 days. The filing is listed beside the story “FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 55 days before publication, inside 60 days. The filing is listed beside the story “FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 59 days before publication, inside 60 days. The filing is listed beside the story “FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 59 days before publication, inside 60 days. The filing is listed beside the story “FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How busy Taiwan Strait has been lately
Taiwan Strait has 49 linked stories in the last 7 days and 49 in the last 30 on the page that also carries “FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva.” The recent pace is rising.
Who gains and who loses around Acadia Healthcare (ACHC)
Companies mentioned with this story
- ACHC Acadia Healthcare
Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence in the 27 Sep 2026 story “FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva.” Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
In “FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence in the 27 Sep 2026 story “FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva.” Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence in the 27 Sep 2026 story “FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva.” Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
Davita (DVA) is linked, with no stored direction, medium confidence in the 27 Sep 2026 story “FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva.” Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
In “FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
What Taiwan Strait means for Acadia Healthcare (ACHC)
The 27 Sep 2026 story “FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva” names Acadia Healthcare (ACHC) because of Taiwan Strait.
Acadia Healthcare (ACHC) is on the page because GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Ascendis Pharma A/S (ASND) is here too. Its reason reads: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the Acadia Healthcare (ACHC) price range
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.
A simple score for Acadia Healthcare (ACHC)
46 out of 100
“FDA Approves Third Treatment for Fibrodysplasia Ossificans Progressiva” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.